Isamsaidu·Oct 24China used to make the cheap parts.Western pharmaceutical giants AstraZeneca among them are increasingly running their early stage clinical trials in china the story of why…
Pharma Now·Sep 24The $15 Trillion Reason Pharma Can’t Ignore Ageing Biology Anymore“Aging is a disease, and that disease is treatable.” — David A. Sinclair, Lifespan: Why We Age — and Why We Don’t Have To
Apackzor·Sep 22Why Molecular Science Labs Are Quietly Becoming the Missing Link Between Pharma, Agriculture, and…A look at how integrated testing labs are replacing the old model of narrow specialization
Aequor Healthcare·Sep 21Can AI Make Regulatory Writing Faster Without Sacrificing Oversight?In regulatory and medical writing, producing a draft is only the beginning. Every number, reference and scientific interpretation needs…
Amelie P·Sep 18What Changed at Rocket Pharmaceuticals in 2026?For years, Rocket Pharmaceuticals was easier to describe as a gene therapy company with a pipeline.A response icon1A response icon1
InZS AssociatesbyZS·Sep 9MFN and the new geography of pricing riskWhy pricing connectivity may reshape launch sequencing and the role of some emerging markets
Bilayours·Sep 6Let’s Talk About Passion!Terbiasa sibuk. Mungkin itu yang seenggaknya gambaran aktivitas masa kecil aku. Dari SD ada aja les nya, ekskul dari sekolah, bahkan…
Rougingsolution·Sep 2Surface roughness (Ra values) in pharma: why it mattersSurface roughness, measured as Ra (arithmetic average roughness), determines whether your pharmaceutical equipment meets GMP standards for…
Nayantara P S·Sep 1Pharmaceutical Traceability Is Turning into a Data ProblemWhen entering today’s modern pharmaceutical manufacturing facilities, you will be faced with not only the machines used for manufacturing.
L7 Informatics·Sep 1The Clinical Trial Paradox & The Pragmatic Middle Path:Unifying Biological Boldness with Enterprise IT Risk ManagementA response icon1A response icon1
